Kabazitaksel Sandoz

Cabazitaxel, the active ingredient in Kabazitaksel Sandoz, is a taxane presented as an intravenous solution for intravenous use. It is approved in the European Union for the treatment of metastatic castration‑resistant prostate cancer in patients who have previously received docetaxel therapy, and is administered under specialist supervision.

GNH USA supplies Kabazitaksel Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide, with manufacturing adhering to EU GMP standards and a focus on reliable cold‑chain logistics for injectable oncology medicines.

Cabazitaxel, a taxane chemotherapy agent, is specifically indicated for the treatment of metastatic castration‑resistant prostate cancer (mCRPC) in patients whose disease has progressed after receiving docetaxel‑based chemotherapy. The drug is delivered as an intravenous infusion and is used by oncologists to target rapidly dividing cancer cells, with the clinical goal of extending overall survival, delaying disease progression, and providing symptomatic relief in this advanced disease setting.

Metastatic castration‑resistant prostate cancer: provides a treatment option after docetaxel failure, aiming to extend survival and control disease progression.

Cabazitaxel is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Anemia: decreased red blood cells causing fatigue and weakness. - Fatigue: generalized tiredness affecting daily activities. - Nausea: upset stomach often occurring during or after infusion.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent medical care. - Severe infection: opportunistic bacterial or fungal infections. - Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Pulmonary toxicity: shortness of breath or interstitial lung changes. - Elevated liver enzymes: significant hepatic injury indicated by increased ALT/AST.

Prior to initiating therapy, several safety measures should be observed. - Monitor blood counts: perform complete blood count before each infusion and during treatment to detect neutropenia or anemia. - Assess liver function: check hepatic enzymes and bilirubin prior to therapy and periodically thereafter. - Evaluate cardiac status: obtain baseline ECG in patients with cardiovascular risk factors. - Avoid in patients with known hypersensitivity to cabazitaxel or other taxanes. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Cabazitaxel may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase cabazitaxel exposure and toxicity. - Concurrent myelosuppressive chemotherapy: can exacerbate neutropenia and anemia. - Live vaccines: immunosuppression may reduce vaccine efficacy and increase infection risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug levels and efficacy. - Anticoagulants (e.g., warfarin, DOACs): increased risk of bleeding due to platelet effects. - Other taxanes or microtubule agents: additive neurotoxicity.